150 related articles for article (PubMed ID: 31820313)
1. Clinical significance of plasma MMP-2 and MMP-9 levels as biomarkers for tumor expression in breast cancer patients in Egypt.
Alrehaili AA; Gharib AF; Karam RA; Alhakami RA; El Sawy WH; Abd Elrahman TM
Mol Biol Rep; 2020 Feb; 47(2):1153-1160. PubMed ID: 31820313
[TBL] [Abstract][Full Text] [Related]
2. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients.
Tutton MG; George ML; Eccles SA; Burton S; Swift RI; Abulafi AM
Int J Cancer; 2003 Nov; 107(4):541-50. PubMed ID: 14520690
[TBL] [Abstract][Full Text] [Related]
3. Serum and tissue expression of gelatinase and Twist in breast cancer.
Huang J; Ang L; Liu MQ; Hu HG; Wang J; Zou Q; Zhao Y; Zheng L; Zhao M; Wu ZS
Eur Rev Med Pharmacol Sci; 2014; 18(18):2662-9. PubMed ID: 25317801
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
6. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients.
Ranuncolo SM; Armanasco E; Cresta C; Bal De Kier Joffe E; Puricelli L
Int J Cancer; 2003 Sep; 106(5):745-51. PubMed ID: 12866035
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-9 as a potential tumor marker in breast cancer.
Nanda DP; Sil H; Moulik S; Biswas J; Mandal SS; Chatterjee A
J Environ Pathol Toxicol Oncol; 2013; 32(2):115-29. PubMed ID: 24099425
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients.
Heo DS; Choi H; Yeom MY; Song BJ; Oh SJ
Oncol Rep; 2014 Apr; 31(4):1567-72. PubMed ID: 24481627
[TBL] [Abstract][Full Text] [Related]
9. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
[TBL] [Abstract][Full Text] [Related]
10. Significance of MMP-9 and VEGF-C expression in North Indian women with breast cancer diagnosis.
Thammineni KL; Thakur GK; Kaur N; Banerjee BD
Mol Cell Biochem; 2019 Jul; 457(1-2):93-103. PubMed ID: 30993496
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
[TBL] [Abstract][Full Text] [Related]
12. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
13. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression.
Patel S; Sumitra G; Koner BC; Saxena A
Clin Biochem; 2011 Jul; 44(10-11):869-72. PubMed ID: 21565179
[TBL] [Abstract][Full Text] [Related]
14. Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer.
Zhang M; Teng XD; Guo XX; Li ZG; Han JG; Yao L
Breast; 2013 Jun; 22(3):330-4. PubMed ID: 22995648
[TBL] [Abstract][Full Text] [Related]
15. Expression of Alpha-Enolase (ENO1), Myc Promoter-Binding Protein-1 (MBP-1) and Matrix Metalloproteinases (MMP-2 and MMP-9) Reflect the Nature and Aggressiveness of Breast Tumors.
Cancemi P; Buttacavoli M; Roz E; Feo S
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31416219
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
Wang RX; Chen S; Huang L; Shao ZM
BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
[TBL] [Abstract][Full Text] [Related]
17. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
[TBL] [Abstract][Full Text] [Related]
18. Activity of MMP-2 and MMP-9 in sera of breast cancer patients.
Stankovic S; Konjevic G; Gopcevic K; Jovic V; Inic M; Jurisic V
Pathol Res Pract; 2010 Apr; 206(4):241-7. PubMed ID: 20092959
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
Skerenova M; Mikulova V; Capoun O; Zima T; Tesarova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):272-280. PubMed ID: 28529342
[TBL] [Abstract][Full Text] [Related]
20. Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients.
Farias E; Ranuncolo S; Cresta C; Specterman S; Armanasco E; Varela M; Lastiri J; Pallotta MG; Bal de Kier Joffe E; Puricelli L
Int J Cancer; 2000 Jul; 89(4):389-94. PubMed ID: 10956415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
